✦ LIBER ✦

A comparison of polychemotherapy and melphalan/prednisone for primary remission induction, and interferon-alpha for maintenance treatment, in multiple myeloma. A prospective trial of the German Myeloma Treatment Group

✍ Scribed by D. Peest; H. Deicher; R. Coldewey; R. Leo; R. Bartl; H. Bartels; H.J. Braun; W. Fett; J.T. Fischer; B. Göbel; P. Harms; R. Henke; L. Hoffmann; E.D. Kreuser; W.D. Maier; C.R. Meier; J. Oertel; M. Petit; M. Planker; C. Platzeck; M. Respondek; E. Schäfer; K. Schumacher; M. Stennes; W. Stenzinger; C. Tirier; H. Wagner; H.J. Weh; P. von Wussow; J. Wysk

Book ID: 116166129
Publisher: Elsevier Science
Year: 1995
Tongue: English
Weight: 704 KB
Volume: 31
Category: Article
ISSN: 0959-8049
DOI: 10.1016/0959-8049(94)00452-b

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of melphalan and prednisone w

Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma : Results of Eastern Cooperative Oncology Group study E2479

✍ Martin M. Oken; David P. Harrington; Neil Abramson; Robert A. Kyle; William Knos 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## METHODS. Four hundred seventy-nine previously untreated patients with multiple myeloma from 23 ECOG institutions were enrolled. Treatment, assigned by ran-1 The Virginia Piper Cancer Institute and the Unidomization, consisted of either 4-week cycles of MP or 5-week cycles of VBCMP.

PSY19 THE COST-EFFECTIVENESS OF BORTEZOM

PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES

✍ S.T. Wang; H. Huang; A. Ba-mancini; H. Shi; K. Chen; C. Korves; R. Dhawan; A. Ca 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Comparison of vincristine, carmustine, m

Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-α with melphalan and prednisone (MP) and interferon-α (IFN-α) in patients with good-prognosis multiple myeloma: a prospective randomized study

✍ K. Zervas; A. Pouli; B. Gregoraki; N. Anagnostopoulos; M. A. Dimopoulos; K. Bour 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 126 KB

Maintenance treatment with interferon al

Maintenance treatment with interferon alpha-2b in multiple myeloma: a prospective randomized study from PETHEMA (Program for the Study and Treatment of Hematological Malignancies, Spanish Society of Hematology)

✍ Bladé, J; Miguel, JF San; Escudero, M L; Fontanillas, M; Besalduch, J; Gardella, 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 56 KB

Addition of thalidomide to oral melphala

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

✍ Meral Beksac; Rauf Haznedar; Tulin Firatli-Tuglular; Hakan Ozdogu; Ismet Aydogdu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 186 KB

Comparison of oral melphalan, CCNU, and

Comparison of oral melphalan, CCNU, and BCNU with and without vincristine and prednisone in the treatment of multiple myeloma. Cancer and leukemia group B experience

✍ Gibbons G. Cornwell III; Thomas F. Pajak; Shaul Kochwa; O. Ross McIntyre; Linda 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 586 KB